ClinicalTrials.gg
RecruitingNCT05874414Updated Jul 13, 2026

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

A Phase 1/2 interventional study of GNS561 + Trametinib in Cholangiocarcinoma, sponsored by Genfit. Recruiting at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Genfit · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
98
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 328 studies in Cholangiocarcinoma with a site in United States — 72 open to participants now, 109 under way, 7 of them phase 3. Cholangiocarcinoma · United States.

Planned enrollment
81st of 279
98 · median 44
Started
2023
with 20 others
Phase 1/2
42 of 328
12 open now
Primary completion
2027-12
later than 55 of 108 live
Registered
256th of 328
by date

Among the 328 studies in Cholangiocarcinoma with a site in United States, this one is the 81st largest by planned enrollment of the 279 interventional ones that give a count, is one of 21 that started in 2023, is one of 42 in phase 1/2, reaches primary completion later than 55 of the 108 other live ones, and was the 256th registered.

Cholangiocarcinoma

826 studies on the registry are indexed under Cholangiocarcinoma; 289 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

72 of the 328 studies in Cholangiocarcinoma with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 328 studies in Cholangiocarcinoma with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure of standard-of-care first line therapy

03

Conditions studied

  • Cholangiocarcinoma

Keywords

  • GNS561
  • Cholangiocarcinoma
  • Trametinib
  • Phase1b/2a
  • Bile Duct cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed intrahepatic CCA with a documented KRAS mutation.
  2. Patients greater than or equal to 18 years of age.
  3. Patients must have disease progression that is not amenable to potentially curative treatment.
  4. Patients must have received one or two .
  5. Patients must have at least one by v1.1.
  6. Performance status () 0-1.
  7. Adequate organ baseline function defined as follows: ≥1000 cells/μL, count ≥75,000 cells/μL, ≥9 g/dL, or alanine aminotransferase less than or equal to 3 × , estimated ≥60 mL/min, interval by Fridericia's (QTcF) interval ≤470 msec.
  8. Women of must present with a negative serum pregnancy test and agree to use adequate during the study and until 6 months after the end of treatment. Male patients with women partners of childbearing potential must agree with the contraception procedures of the study protocol.
  9. Patients must be able to understand and be willing to comply with the requirements of the study protocol.
  10. Patients participate voluntarily and sign form(s).

Exclusion criteria

Exclusion criteria:

  1. Previous treatment with a MEK inhibitor or autophagy inhibitor.
  2. Previous treatment with three or more .
  3. Extrahepatic CCA with recent (within 6 weeks) placement of a stent or episodes of unstable biliary stents (manifest as obstruction, migration of the stent, infevtion or mechanical failure of the stent) within 6 weeks according to investigator's judgement.
  4. Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:

    1. Cardiovascular disorders: congestive heart failure ≥ class 2 or (LVEF) \<50%, arrythmias or cardiac conduction abnormalities. Uncontrolled arterial hypertension or inadequately controlled arterial hypertension, at the discretion of the investigator, based on an average of = >3 BP readings over = >2 sessions.
    2. Patients who have retinal condition (retinal tear, exudate, hemorrhage) or history of retinal vein occlusion or central serous retinopathy or retinal pigment epithelial detachment.
    3. History of interstitial lung disease or pneumonitis.
    4. Patients who have pleural effusion or ascites.
    5. Patients who have neurological condition (e.g., tremor, ataxia, hypotension, confusion), history of seizures or active central nervous system .
    6. Impairment of gastrointestinal function or gastrointestinal disease (e.g., diarrhea, active ulcer disease, history of gastrointestinal perforation/hemorrhage, malabsorption or other conditions that under the judgment of the principal investigator (PI) may impair absorption of study drugs).
    7. Patients who are taking antineoplastic drugs for concomitant cancer or history of other than CCA within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate > 90%) such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer.
    8. Any other condition that would, in the Investigator s judgment, contraindicate the patients' participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection, unable to swallow medication, social/psychological issues, etc).
  5. Known active viral hepatitis, including and .
  6. Patients with known allergic reaction to quinoline derivatives (e.g., quinine, chloroquine, mefloquine) and/or to study drugs.
  7. Patients who have not recovered for certain AEs due to previous lines of therpay.
  8. Female patients who are pregnant or lactating at the time of enrollment.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
98 participants (estimated)

Study arms

  • Experimental
    GNS561+Trametinib

    Phase 1b Dose Finding Patients will receive GNS561 (50mg QD; 100mg QD; 150mg; 200mg QD) and trametinib (2mg QD; 1.5mg QD; 1mg QD) in a dose escalation/de-escalation design to determine the maximum tolerated dose (MTD) of the combination. Experimental: Phase 2a Patients will receive GNS561 and trametinib at the recommended dose of the combination determined during Phase 1b

    Drug: GNS561 + Trametinib

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicity (DLT) of GNS561 with trametinib (Phase 1b)

    Defined as Treatment Emergent Adverse Event (TEAE) being at least possibly related to study drug: With Grade ≥ 3 (using NCI CTCAE Version 5.0 or higher as applicable) such as specified in the protocol

    Time frame: At the end of Cycle 1 (each Cycle is 21 days)

  2. Objective response rate (ORR) of the combination of GNS561 with trametinib (Phase 2a)

    Defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)

    Time frame: Up to 11 months (estimated)

Secondary outcomes

  1. Duration of response (DoR)

    Defined as the duration between first documentation of CR or PR to first documentation of disease progression or death using RECIST v1.1

    Time frame: Up to 11 months (estimated)

  2. Progression-free survival (PFS)

    Defined as the time from the date of first dose of study drug to the date of first documented disease progression or death

    Time frame: Up to 11 months (estimated)

  3. Time To Progression (TTP)

    Defined as the time from first dose of study drug to the date of first documented disease progression.

    Time frame: Up to 11 months (estimated)

  4. Disease Control Rate (DCR)

    defined as the proportion of patients with a best overall response of CR or PR or stable disease (SD) using RECIST v1.1

    Time frame: Up to 11 months (estimated)

  5. Time To Response (TTR)

    Defined as the time from first dose of study drug to first documentation of CR or PR using RECIST v1.1

    Time frame: Up to 11 months (estimated)

  6. Overall Survival (OS) time

    Defined as the time from the date of first dose of study drug to the date of death due to any cause.

    Time frame: Up to approximately 42 months

  7. Incidence and severity of treatment emergent adverse event (TEAEs), incidence of serious adverse events (SAEs), incidence of TRAEs, incidence of adverse events of special interest (AESIs), rate of treatment discontinuation or interruption for TRAEs

    graded according to NCI CTCAE v5.0

    Time frame: Up to 11 months (estimated)

  8. Incidence of clinically significant changes or abnormalities from physical examinations, ophthalmologic assessments, vital signs, performance scores, laboratory results, ECGs, echocardiograms or multigated acquisition scans

    Time frame: Up to 11 months (estimated)

  9. Drug concentration in plasma for GNS561 and trametinib

    Time frame: Predose to Day 21 of Cycle 1 and predose to Day 21 of Cycle 2 (each Cycle is 21 days)

07

Study locations

9 of 11 sites recruiting
  • USC Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
    Recruiting
    • USC Norris Comprehensive Cancer Center · Contact
  • LACN Aneheim Flagship Office
    Los Angeles, California 92805, United States
    Recruiting
    • LACN Aneheim Flagship Office · Contact
  • Orlando Health
    Orlando, Florida 32806, United States
    Recruiting
    • Orlando Health · Contact
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
    Recruiting
    • Moffitt Cancer Center · Contact
  • University Of Chicago Medical Center
    Chicago, Illinois 60637, United States
    Recruiting
    • University Of Chicago Medical Center · Contact
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
    Terminated

    Not enrolling at this site.

  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
    Terminated

    Not enrolling at this site.

  • University of Texas, MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • The University of Texas, MD Anderson Cancer Center · Contact
  • University of Virginia Comprehensive Cancer Center
    Charlottesville, Virginia 22908, United States
    Recruiting
    • University of Virginia Health System · Contact
  • Froedtert Hospital and the Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Medical College of Wisconsin · Contact
  • Pan American Center for Oncology Trials, LLC
    Rio Piedras, Puerto Rico 00935, Puerto Rico
    Recruiting
    • Pan American Center for Oncology Trials, LLC · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Dec 2027, 52 months after the start.

Of 40 phase 1/2 interventional studies under Cholangiocarcinoma, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 77. This study's planned 52 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2023
First posted
May 24, 2023
StartActual
Aug 21, 2023
Primary completionEst.
Dec 2027
CompletionEst.
Jun 2028
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05874414
Lead sponsor
Genfit
Responsible party
Sponsor
First posted
May 24, 2023
Start date
Aug 21, 2023
Primary completion
Dec 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Jul 13, 2026

Study contacts

Pejvack MOTLAGH, CMO
Contact
contact@genfit.com
+33320164092
Pejvack MOTLAGH, CMO
Contact
pejvack.motlagh@genfit.com
+33320164092
Pejvack MOTLAGH, CMO
study director · Genfit

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezurpimtrostat · Trametinib

Start the discussion